Bristol Myers Squibb, Cellares
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares
Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.
Bristol Myers, Cellares ink $380M CAR-T therapies supply deal
Bristol Myers Squibb (NYSE:BMY) on Monday announced a $380M deal with contract manufacturer Cellares to produce CAR T cell therapies. As part of the worldwide capacity reservation and supply deal, Bristol Myers Squibb (BMY) will utilize Cellares’ proprietary cell therapy manufacturing platform,
With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellares
Bristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating to a $255 million series C funding round in August | Eight months after participating in a $255 million funding round in cell therapy contract manufacturer Cellares,
Bristol Myers Signs $380 Million CAR-T Therapies Supply Deal With Cellares
(Reuters) - Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients. Copyright 2024 Thomson Reuters.
Bristol Myers Squibb, Cellares Ink $380M Deal to Manufacture CAR T-Cell Therapies
Per the agreement, Cellares will integrate and automate some of Bristol Myers Squibb’s CAR T-cell therapies into its Cell Shuttle program.
Bristol Myers Squibb, Cellares announce a $380 mn worldwide capacity reservation and supply agreement for manufacture of CAR T cell therapies
Bristol Myers Squibb, Cellares announce a $380 mn worldwide capacity reservation and supply agreement for manufacture of CAR T cell therapies: Princeton, New Jersey Tuesday, April
Seeking Alpha on MSN12h
Bristol-Myers Earnings Preview: Major near-term headwinds invites worries about Q1 results
Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market ...
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers ...
Bristol-Myers Squibb earnings preview: what to expect
Bristol-Myers Squibb releases figures for Q1 on April 25.Wall Street analysts expect Bristol-Myers Squibb will release losses per share of ...
Is Bristol Myers Squibb A Buy At These Bottom Levels?
For context, BMY has previously offered a relatively promising FY2024 guidance, with revenue growth of low single digits and ...
FiercePharma1d
Novartis nominates former Bristol Myers CEO Giovanni Caforio as its new chair. Will M&A deals follow?
Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. | ...
Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
The chart below, which you can click on for greater detail, shows that Bristol-Myers Squibb had US$39.8b in debt in December ...
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S ...